Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis

Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family. It is raised in various cardiovascular diseases, but its value in predicting disease severity or mortality outcomes has been controversial. Therefore, we conducted a systematic review and meta-analysis t...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology. Heart & vasculature 2021-12, Vol.37, p.100887-100887, Article 100887
Main Authors: Ip, Christina, Luk, King Sum, Yuen, Vincent Lok Cheung, Chiang, Lorraine, Chan, Ching Ki, Ho, Kevin, Gong, Mengqi, Lee, Teddy Tai Loy, Leung, Keith Sai Kit, Roever, Leonardo, Bazoukis, George, Lampropoulos, Konstantinos, Li, Ka Hou Christien, Tse, Gary, Liu, Tong
Format: Article
Language:English
Subjects:
Coronary artery disease
Heart failure
Mortality
Review
Severity
Soluble suppression of tumorigenicity 2
sST2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family. It is raised in various cardiovascular diseases, but its value in predicting disease severity or mortality outcomes has been controversial. Therefore, we conducted a systematic review and meta-analysis to determine whether sST2 levels differed between survivors and non-survivors of patients with cardiovascular diseases, and whether elevated sST2 levels correlated with adverse outcomes. PubMed and Embase were searched until 23rd June 2021 for studies that evaluated the relationship between sST2 levels and cardiovascular disease severity or mortality. A total of 707 entries were retrieved from both databases, of which 14 studies were included in the final meta-analysis. In acute heart failure, sST2 levels did not differ between survivors and non-survivors (mean difference [MD]: 24.2 ± 13.0 ng/ml; P = 0.06; I2: 95%). Elevated sST2 levels tend to be associated with increased mortality risk (hazard ratio [HR]: 1.12, 95 %CI: 0.99–1.27, P = 0.07; I2: 88%). In chronic heart failure, sST2 levels were higher in non-survivors than in survivors (MD: 0.19 ± 0.04 ng/ml; P = 0.001; I2: 0%) and elevated levels were associated with increased mortality risk (HR: 1.64, 95% CI: 1.27–2.12, P 
ISSN:2352-9067
2352-9067
DOI:10.1016/j.ijcha.2021.100887